Modifying metabolic and immune hallmarks of cancer by a copper complex

被引:0
|
作者
Chu, Chengyan [1 ]
Zhang, Yunhua [2 ]
Qian, Chengyuan [1 ]
Yang, Xiu-Zhi [2 ]
Shang, Yicun [1 ]
Guo, Zijian [2 ]
Wang, Xiaoyong [1 ]
机构
[1] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, Nanjing 210023, Peoples R China
[2] Nanjing Univ, Sch Chem & Chem Engn, State Key Lab Coordinat Chem, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
cancer hallmark; copper complex; cuproptosis; lactate metabolism; immunomodulation; CUPROPTOSIS-RELATED GENES; CELL-DEATH; LACTIC-ACID; T-CELLS; LACTATE; MITOCHONDRIA; IMMUNOSUPPRESSION; RESPONSES; INNATE; IONS;
D O I
10.1007/s11426-024-2316-4
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Metabolic adaptation of cancer cells is a key tactic for maintaining their tumorigenicity and viability in the tumor immune microenvironment (TIME). Concurrent modulation on the metabolic pathway and immune system could change the living condition of cancer cells and potentiate the efficacy of anticancer drugs. A copper complex (DDCu) was designed to influence the energy metabolism of cancer cells and reshape the TIME. DDCu restrained the production and transportation of lactate by inhibiting the expression of lactate dehydrogenase and monocarboxylate transporter 4, thereby altering the metabolic pathway of cancer cells and improving the acidic tumor microenvironment. Meantime, DDCu was reduced to Cu+ by cellular glutathione to react with lipoylated proteins of the tricarboxylic acid cycle and destabilize the Fe-S cluster proteins, leading to the aggregation of dihydrolipoamide S-acetyltransferase and cuproptosis in cancer cells. Furthermore, DDCu promoted the polarization of macrophages from the M2 to M1 phenotype, activated CD4+ and CD8+ T cells, and reversed the immunosuppression. As a result, DDCu inhibited the tumor growth through a synergy between metabolic regulation and immunomodulation.
引用
收藏
页码:1051 / 1066
页数:16
相关论文
共 50 条
  • [31] Metabolic regulation in the immune response to cancer
    Wu, Qi
    Yu, Xin
    Li, Juanjuan
    Sun, Shengrong
    Tu, Yi
    CANCER COMMUNICATIONS, 2021, 41 (08) : 661 - 694
  • [32] The cancer metabolic reprogramming and immune response
    Longzheng Xia
    Linda Oyang
    Jinguan Lin
    Shiming Tan
    Yaqian Han
    Nayiyuan Wu
    Pin Yi
    Lu Tang
    Qing Pan
    Shan Rao
    Jiaxin Liang
    Yanyan Tang
    Min Su
    Xia Luo
    Yiqing Yang
    Yingrui Shi
    Hui Wang
    Yujuan Zhou
    Qianjin Liao
    Molecular Cancer, 20
  • [33] Metabolic regulation of immune responses to cancer
    Wissfeld, Jannis
    Werner, Anke
    Yan, Xin
    Ten Bosch, Nora
    Cui, Guoliang
    CANCER BIOLOGY & MEDICINE, 2022, 19 (11) : 1528 - 1542
  • [34] The cancer metabolic reprogramming and immune response
    Xia, Longzheng
    Oyang, Linda
    Lin, Jinguan
    Tan, Shiming
    Han, Yaqian
    Wu, Nayiyuan
    Yi, Pin
    Tang, Lu
    Pan, Qing
    Rao, Shan
    Liang, Jiaxin
    Tang, Yanyan
    Su, Min
    Luo, Xia
    Yang, Yiqing
    Shi, Yingrui
    Wang, Hui
    Zhou, Yujuan
    Liao, Qianjin
    MOLECULAR CANCER, 2021, 20 (01)
  • [35] Allicin and Cancer Hallmarks
    Talib, Wamidh H.
    Baban, Media Mohammed
    Azzam, Aya O.
    Issa, Jenan J.
    Ali, Alaa Y.
    Alsuwais, Alia Kh.
    Allala, Sana
    AL Kury, Lina T.
    MOLECULES, 2024, 29 (06):
  • [36] The systemic hallmarks of cancer
    Paul, Doru
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2020, 6
  • [37] AKT and the Hallmarks of Cancer
    Sementino, Eleonora
    Hassan, Dalal
    Bellacosa, Alfonso
    Testa, Joseph R.
    CANCER RESEARCH, 2024, 84 (24) : 4126 - 4139
  • [38] What are the hallmarks of cancer?
    Lazebnik, Yuri
    NATURE REVIEWS CANCER, 2010, 10 (04) : 232 - 233
  • [39] Metabolic regulation of immune responses to cancer
    Jannis Wifeld
    Anke Werner
    Xin Yan
    Nora ten Bosch
    Guoliang Cui
    Cancer Biology & Medicine, 2022, 19 (11) : 1528 - 1542
  • [40] Heparanase and the hallmarks of cancer
    Jayatilleke, Krishnath M.
    Hulett, Mark D.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18 (01)